Literature DB >> 25326112

Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway.

Yinan Li1, Sengwang Fu, Haiying Chen, Qian Feng, Yunjie Gao, Hanbing Xue, Zhizheng Ge, Jingyuan Fang, Shudong Xiao.   

Abstract

BACKGROUND: Thalidomide is effective in the treatment of angiodysplasia. The mechanisms underlying its activity may be associated with inhibition of angiogenic factors. It was recently shown that Slit2/Robo1 signaling plays a role in angiogenesis.
PURPOSE: The aim of this study was to explore the expression and effects of Robo1 and Slit2 in angiodysplasia and to identify the possible therapeutic mechanisms of thalidomide.
METHOD: Slit2 and Robo1 expression were analyzed in tissue samples and human umbilical vein endothelial cells (HUVECs) treated with thalidomide using a combination of laboratory assays that were able to detect functional activity.
RESULTS: Slit2, Robo1 and vascular endothelial growth factor (VEGF) were strongly expressed in five angiodysplasia lesions out of seven cases, while expression was low in one out of seven normal tissues. Exposure of HUVECs to recombinant N-Slit2 resulted in an increase in VEGF levels and stimulated proliferation, migration and tube formation. These effects were blocked by an inhibitor of PI3K and thalidomide.
CONCLUSIONS: Robo1 and Slit2 may have important roles in the formation of gastrointestinal vascular malformation. High concentrations of Slit2 increased the levels of VEGF in HUVECs via signaling through the PI3K/Akt pathway-an effect that could be inhibited by thalidomide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25326112     DOI: 10.1007/s10620-014-3257-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Switching repulsion to attraction: changing responses to slit during transition in mesoderm migration.

Authors:  S G Kramer; T Kidd; J H Simpson; C S Goodman
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

Review 2.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 3.  Axon guidance molecules in vascular patterning.

Authors:  Ralf H Adams; Anne Eichmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03-31       Impact factor: 10.005

4.  Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Authors:  Silvio Danese; Miquel Sans; David M Spencer; Ivy Beck; Fernando Doñate; Marian L Plunkett; Carol de la Motte; Raymond Redline; David E Shaw; Alan D Levine; Andrew P Mazar; Claudio Fiocchi
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Increased expression of angiogenic factors in human colonic angiodysplasia.

Authors:  F Junquera; E Saperas; I de Torres; M T Vidal; J R Malagelada
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

6.  Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.

Authors:  Y Fujio; K Walsh
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

Review 7.  Vascular lesions of the gastrointestinal tract.

Authors:  Jaroslaw Regula; Ewa Wronska; Jacek Pachlewski
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

8.  Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death.

Authors:  Jürgen Knobloch; Ingo Schmitz; Katrin Götz; Klaus Schulze-Osthoff; Ulrich Rüther
Journal:  Mol Cell Biol       Date:  2008-01       Impact factor: 4.272

9.  Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.

Authors:  Evangelos Terpos; Nikolaos Kanellias; Dimitrios Christoulas; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Onco Targets Ther       Date:  2013-05-10       Impact factor: 4.147

10.  Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis.

Authors:  Sonia L Hernandez; Debarshi Banerjee; Jessica J Kandel; Darrell J Yamashiro; Alejandro Garcia; Thaned Kangsamaksin; Wei-Yi Cheng; Dimitris Anastassiou; Yasuhiro Funahashi; Angela Kadenhe-Chiweshe; Carrie J Shawber; Jan K Kitajewski
Journal:  Vasc Cell       Date:  2013-09-25
View more
  6 in total

Review 1.  Advances in the Medical Management of Vascular Anomalies.

Authors:  Kiersten W Ricci
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

2.  Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway.

Authors:  Qiqin Song; Hongyue Zhang; Jinan He; Hongyan Kong; Ran Tao; Yu Huang; Haijing Yu; Zhongwei Zhang; Zhiyong Huang; Lai Wei; Chenghai Liu; Likui Wang; Qin Ning; Jiaquan Huang
Journal:  Ther Adv Med Oncol       Date:  2020-08-27       Impact factor: 8.168

3.  Do Wortmannin and Thalidomide induce apoptosis by autophagy inhibition in 4T1 breast cancer cells in vitro and in vivo?

Authors:  Elgin Turkoz Uluer; Pinar Kilicaslan Sonmez; Damla Akogullari; Melike Onal; Gamze Tanriover; Sevinc Inan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity.

Authors:  Preeti Viswanathan; Priya Gupta; Sorabh Kapoor; Sanjeev Gupta
Journal:  J Hepatol       Date:  2016-07-12       Impact factor: 25.083

Review 5.  Thalidomide-induced teratogenesis: history and mechanisms.

Authors:  Neil Vargesson
Journal:  Birth Defects Res C Embryo Today       Date:  2015-06-04

Review 6.  Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach

Authors:  Wenjie Yang; Dandan Wang; Litao Huang; Yue Chen; Shu Wen; Qi Hong; Deying Kang
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.